These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22454074)

  • 1. Identification of peptides for tissue-specific delivery.
    Heemskerk H
    Methods Mol Biol; 2012; 867():379-92. PubMed ID: 22454074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of antisense-mediated exon skipping.
    van Ommen GJ; van Deutekom J; Aartsma-Rus A
    Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
    Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues.
    Gait MJ
    Cell Mol Life Sci; 2003 May; 60(5):844-53. PubMed ID: 12827274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.
    Abes S; Moulton HM; Clair P; Prevot P; Youngblood DS; Wu RP; Iversen PL; Lebleu B
    J Control Release; 2006 Dec; 116(3):304-13. PubMed ID: 17097177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic and tissue-specific protein transduction domains identification, characterization, and therapeutic application.
    Zahid M; Lu X; Mi Z; Robbins PD
    Adv Genet; 2010; 69():83-95. PubMed ID: 20807603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic delivery of antisense oligomer in animal models and its implications for treating DMD.
    Lu QL; Wu B
    Methods Mol Biol; 2012; 867():393-405. PubMed ID: 22454075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells.
    Shadidi M; Sioud M
    FASEB J; 2003 Feb; 17(2):256-8. PubMed ID: 12490548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exon skipping quantification by real-time PCR.
    Ferlini A; Rimessi P
    Methods Mol Biol; 2012; 867():189-99. PubMed ID: 22454062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides.
    Aartsma-Rus A; Janson AA; Heemskerk JA; De Winter CL; Van Ommen GJ; Van Deutekom JC
    Ann N Y Acad Sci; 2006 Oct; 1082():74-6. PubMed ID: 17145928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspects of the transport and delivery of antisense oligonucleotides.
    Juliano RL; Yoo H
    Curr Opin Mol Ther; 2000 Jun; 2(3):297-303. PubMed ID: 11249624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.
    Wu B; Moulton HM; Iversen PL; Jiang J; Li J; Li J; Spurney CF; Sali A; Guerron AD; Nagaraju K; Doran T; Lu P; Xiao X; Lu QL
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14814-9. PubMed ID: 18806224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular delivery of peptide nucleic acid by cell-penetrating peptides.
    Kilk K; Langel U
    Methods Mol Biol; 2005; 298():131-41. PubMed ID: 16044544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo.
    Mueller J; Gaertner FC; Blechert B; Janssen KP; Essler M
    Mol Cancer Res; 2009 Jul; 7(7):1078-85. PubMed ID: 19584266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
    Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.